Acute haemolytic transfusion reaction after transfusion of fresh frozen plasma in a neonate-Preventable by using solvent/detergent-treated pooled plasma?


Journal

Transfusion medicine (Oxford, England)
ISSN: 1365-3148
Titre abrégé: Transfus Med
Pays: England
ID NLM: 9301182

Informations de publication

Date de publication:
Apr 2023
Historique:
revised: 26 08 2022
received: 07 06 2022
accepted: 29 09 2022
medline: 4 4 2023
pubmed: 19 10 2022
entrez: 18 10 2022
Statut: ppublish

Résumé

Plasma is a commonly used blood product and is available in the form of fresh frozen plasma (FFP) or pooled solvent/detergent-treated plasma. In the Netherlands, solvent/detergent-treated plasma has become the standard product in the adult population since several years, but for neonatal use, FFP remains the product of preference. A preterm neonate developed lung bleeding at day 8 postpartum, for which intubation and mechanical ventilation was required and transfusions with packed red blood cells and plasma, in the form of FFP, were given. Five hours after transfusion, a red discoloration of the urine occurred. An acute haemolytic transfusion was suspected, confirmed by laboratory investigations (fast decrease in haemoglobin, increased free haemoglobin, decreased haptoglobin, increased lactate dehydrogenase and a positive direct antiglobulin test [IgG 2+]). Additional research showed that the FFP product contained nonspecific auto-antibodies that reacted with the transfused erythrocytes, most test erythrocytes and the donor's own erythrocytes. A neonate experienced an acute haemolytic reaction, most probably caused by administrating a FFP product containing auto-antibodies. If transfused with solvent/detergent-treated plasma, such antibodies would have been diluted or captured. This case adds a new argument to the discussion on expanding the use of solvent/detergent-treated plasma to the paediatric population.

Sections du résumé

BACKGROUND BACKGROUND
Plasma is a commonly used blood product and is available in the form of fresh frozen plasma (FFP) or pooled solvent/detergent-treated plasma. In the Netherlands, solvent/detergent-treated plasma has become the standard product in the adult population since several years, but for neonatal use, FFP remains the product of preference.
DESCRIPTION METHODS
A preterm neonate developed lung bleeding at day 8 postpartum, for which intubation and mechanical ventilation was required and transfusions with packed red blood cells and plasma, in the form of FFP, were given. Five hours after transfusion, a red discoloration of the urine occurred. An acute haemolytic transfusion was suspected, confirmed by laboratory investigations (fast decrease in haemoglobin, increased free haemoglobin, decreased haptoglobin, increased lactate dehydrogenase and a positive direct antiglobulin test [IgG 2+]). Additional research showed that the FFP product contained nonspecific auto-antibodies that reacted with the transfused erythrocytes, most test erythrocytes and the donor's own erythrocytes.
CONCLUSION CONCLUSIONS
A neonate experienced an acute haemolytic reaction, most probably caused by administrating a FFP product containing auto-antibodies. If transfused with solvent/detergent-treated plasma, such antibodies would have been diluted or captured. This case adds a new argument to the discussion on expanding the use of solvent/detergent-treated plasma to the paediatric population.

Identifiants

pubmed: 36257670
doi: 10.1111/tme.12926
doi:

Substances chimiques

Detergents 0
Solvents 0
Antibodies 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

174-178

Informations de copyright

© 2022 The Authors. Transfusion Medicine published by John Wiley & Sons Ltd on behalf of British Blood Transfusion Society.

Références

Tinmouth A. Assessing the rationale and effectiveness of frozen plasma transfusions: an evidence-based review. Hematol Oncol Clin North Am. 2016;30(3):561-572.
TRIP foundation (Transfusion and Transplantation Reaction in Patients). TRIP report 2019 hemovigilance, extended version. 2019.
Hellstern P. Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma? Transfus Apher Sci. 2008;39(1):69-74.
Camazine MN, Karam O, Colvin R, et al. Outcomes related to the use of frozen plasma or pooled solvent/detergent-treated plasma in critically ill children. Pediatr Crit Care Med. 2017;18(5):e215-e223.
Spinella PC, Borasino S, Alten J. Solvent/detergent-treated plasma in the Management of Pediatric Patients who Require Replacement of multiple coagulation factors: an open-label, multicenter, Post-Marketing Study. Front Pediatr. 2020;8:572.
Chekrizova V, Murphy WG. Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med. 2006;16(2):85-91.
Kalsi AS, Al-Azzawi O, Gill R. Comparison of the coagulation effect achieved by OctaplasLG versus fresh frozen plasma in pediatric cardiac surgical patients. Clin Appl Thromb Hemost. 2018;24(8):1327-1332.
Witt V, Pichler H, Beiglboeck E, Kursten F, Weidner L. Changes in hemostasis caused by different replacement fluids and outcome in therapeutic plasma exchange in pediatric patients in a retrospective single center study. Transfus Apher Sci. 2017;56(1):59-65.
Octapharma GmbH. Product Information Omniplasma 45-70 mg/Ml Solution for Infusion. 2021.
Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH Technology Report. Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enevloped viruses: an economic analysis and budget impact analysis. 2011.
Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood. 1988;72(5):1651-1657.
Keir AK, Stanworth SJ. Neonatal plasma transfusion: an evidence-based review. Transfus Med Rev. 2016;30(4):174-182.
Goel R, Josephson CD. Recent advances in transfusions in neonates/infants. F1000Res. 2018;7:609.
New HV, Berryman J, Bolton-Maggs PH, et al. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol. 2016;175(5):784-828.
Houben NAM, Heeger LE, Stanworth SJ, et al. Changes in the use of fresh-frozen plasma transfusions in preterm neonates: a single center experience. J Clin Med. 2020;9(11):3789.
Otrock ZK, Liu C, Grossman BJ. Transfusion-related acute lung injury risk mitigation: an update. Vox Sang. 2017;112(8):694-703.
Norfolk DR, Glaser A, Kinsey S. American fresh frozen plasma for neonates and children. Arch Dis Child. 2005;90(1):89-91.
Arora S, Marwaha N, Dhawan HK, Rao KLN. Dedicated donor unit transfusions reduces donor exposure in pediatric surgery patients. Asian J Transfus Sci. 2017;11(2):124-130.
Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. Transfusion Handboek 10.2 Neonatal tranfusion. Accessed February 15, 2022.

Auteurs

Linda M Henricks (LM)

Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands.

Elise J Huisman (EJ)

Department of Paediatric Haematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands.
Department of Transfusion Medicine, Sanquin, Amsterdam, the Netherlands.

Enrico Lopriore (E)

Department of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, the Netherlands.

Jessie S Luken (JS)

Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, the Netherlands.

Masja de Haas (M)

Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, the Netherlands.
Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.

Claudia S Ootjers (CS)

Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.

Arjan Albersen (A)

Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH